Event JSON
{
"id": "7926faacf273f6d1846a55752a279e0e9d7622ee8768f2a00a9a4cad005ce5ef",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1748607153,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/abbvie-inc-abbv-pipeline-advances-041910851.html"
],
[
"subject",
"AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat"
],
[
"published_at",
"1748492350"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/w4YPOci67cxa36YztUhOig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/400953731f42e8d1de6ad8fe09059c8b"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/w4YPOci67cxa36YztUhOig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/400953731f42e8d1de6ad8fe09059c8b"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"AbbVie Inc. presented clinical data for its ADCs, Temab-A and ABBV-706, at the ASCO 2025 Annual Meeting, highlighting their potential in treating non-small cell lung cancer, small cell lung cancer, and high-grade neuroendocrine neoplasms. The company's proprietary Top1i payload induces targeted cancer cell death, demonstrating the company's commitment to addressing difficult-to-treat tumors."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://s.yimg.com/ny/api/res/1.2/w4YPOci67cxa36YztUhOig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/400953731f42e8d1de6ad8fe09059c8b\n\nhttps://finance.yahoo.com/news/abbvie-inc-abbv-pipeline-advances-041910851.html",
"sig": "3cfe2f2033000ae9ec7cbd59c08518eb4bb02552cbdb1174f6902502f0c5f8109740b0373886e6eec013b64c1830111d7a057fb2a6d7f79c2371ad66d2aa2e30"
}